CN113813367B - Composition for treating sensitive skin and preparation method and application thereof - Google Patents
Composition for treating sensitive skin and preparation method and application thereof Download PDFInfo
- Publication number
- CN113813367B CN113813367B CN202111163063.5A CN202111163063A CN113813367B CN 113813367 B CN113813367 B CN 113813367B CN 202111163063 A CN202111163063 A CN 202111163063A CN 113813367 B CN113813367 B CN 113813367B
- Authority
- CN
- China
- Prior art keywords
- composition
- preparation
- skin
- glucan
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 230000037307 sensitive skin Effects 0.000 title description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 30
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 30
- 229920000057 Mannan Polymers 0.000 claims abstract description 27
- 241000235342 Saccharomycetes Species 0.000 claims abstract description 15
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 15
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 15
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 15
- 229920001184 polypeptide Polymers 0.000 claims abstract description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 14
- 208000025157 Oral disease Diseases 0.000 claims abstract description 10
- 208000030194 mouth disease Diseases 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 201000001245 periodontitis Diseases 0.000 claims abstract description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 42
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 230000001737 promoting effect Effects 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 13
- 229920002125 Sokalan® Polymers 0.000 claims description 12
- 229960001631 carbomer Drugs 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 9
- 230000029663 wound healing Effects 0.000 claims description 9
- 208000002925 dental caries Diseases 0.000 claims description 8
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 7
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 claims description 7
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 claims description 7
- 206010072170 Skin wound Diseases 0.000 claims description 6
- 206010053615 Thermal burn Diseases 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 2
- 239000000498 cooling water Substances 0.000 claims description 2
- 208000002399 aphthous stomatitis Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 208000025865 Ulcer Diseases 0.000 abstract description 7
- 208000027418 Wounds and injury Diseases 0.000 abstract description 7
- 230000008439 repair process Effects 0.000 abstract description 7
- 231100000397 ulcer Toxicity 0.000 abstract description 7
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 208000002064 Dental Plaque Diseases 0.000 abstract description 4
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 3
- 206010000496 acne Diseases 0.000 abstract description 3
- 210000003205 muscle Anatomy 0.000 abstract description 3
- 208000008960 Diabetic foot Diseases 0.000 abstract description 2
- 206010042496 Sunburn Diseases 0.000 abstract description 2
- 210000005036 nerve Anatomy 0.000 abstract description 2
- 230000002792 vascular Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 23
- 238000012360 testing method Methods 0.000 description 22
- 239000000243 solution Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 12
- 229960005150 glycerol Drugs 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 241000194019 Streptococcus mutans Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 241000605894 Porphyromonas Species 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000002292 Radical scavenging effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- -1 hydroxyl free radical Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000001680 brushing effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 3
- 230000007505 plaque formation Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 208000024283 Gingival haemorrhages Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 1
- 229940082484 carbomer-934 Drugs 0.000 description 1
- 229940043234 carbomer-940 Drugs 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 230000019305 fibroblast migration Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000006254 rheological additive Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a composition, a preparation method and application thereof. The preparation raw materials of the composition comprise: 5-20 parts of beta-glucan, 5-30 parts of mannan, 8-15 parts of saccharomycetes polypeptides and 1-20 parts of sodium hyaluronate. The composition prepared by the invention can repair damaged skin and treat oral diseases by a specific synergistic effect through the preparation raw materials; has obvious curative effects on sensitive muscles, sunburn skin, acne, diabetic foot, vascular nerve ulcers, superficial wound surfaces, dental ulcers, dental plaque, periodontitis and the like.
Description
Technical Field
The invention relates to the field of medicines, in particular to a composition for treating sensitive skin, a preparation method and application thereof.
Background
The modern society has appeared a large amount of skin problems such as skin allergy, sensitive muscle, acne, eczema, dermatitis because of the reasons such as fast pace of life, great pressure of life and work, the time of work is irregular, and in addition people's living standard is also increasing day by day, has put forward higher demand to the serial problem that skin damage leads to. In the existing solutions, most of the medicines are hormones, and certain side effects and drug resistance exist; cosmetic products and other skin care products are also available, but mainly keep moisture, and have poor healing effects or long healing time on damaged skin. Oral diseases including oral mucosa damage such as dental ulcer, tooth decay, oral erosion, gingival hemorrhage, periodontitis, gingivitis and the like can seriously affect the life quality of people, and even bring about other complications such as diseases of kidneys, coronary arteries or livers, and the increasingly developed oral market is urgently required to have oral products with outstanding effects and no side effects.
The present application provides a composition with outstanding effect and no side effect, which can effectively promote skin wound healing and has a certain treatment effect on oral diseases.
Disclosure of Invention
The present invention aims to solve at least one of the technical problems existing in the prior art. Therefore, the invention provides a composition which can effectively promote skin wound healing and has a certain treatment effect on oral diseases.
The invention also provides a preparation method of the composition.
The invention also provides application of the composition.
According to an embodiment of the first aspect of the present invention, the composition is prepared from the following raw materials: 5-20 parts of beta-glucan, 5-30 parts of mannan, 8-15 parts of saccharomycetes polypeptides and 1-20 parts of sodium hyaluronate.
According to some embodiments of the invention, the composition comprises the following raw materials in mass fraction: 5-10 parts of beta-glucan, 15-20 parts of mannan, 8-12 parts of saccharomycete multi-peptide and 3-8 parts of sodium hyaluronate.
According to some embodiments of the invention, the composition comprises the following raw materials in mass fraction: 8-12 parts of beta-glucan, 18-22 parts of mannan, 8-12 parts of saccharomycete polypeptides and 3-6 parts of sodium hyaluronate.
According to some embodiments of the invention, the composition comprises the following raw materials in mass fraction: 10 parts of beta-glucan, 20 parts of mannan, 10 parts of saccharomycetes polypeptides and 5 parts of sodium hyaluronate.
According to some embodiments of the invention, the preparation raw materials of the composition further comprise: glycerol, carbomer, sodium methylparaben and/or triethanolamine.
According to some embodiments of the invention, the composition further comprises the following raw materials in mass fraction: 5-15 parts of carbomer, 20-40 parts of glycerol, 1-5 parts of sodium methylparaben and 5-20 parts of triethanolamine.
According to some embodiments of the invention, the composition further comprises the following raw materials in mass fraction: 30 parts of glycerol, 10 parts of carbomer, 1 part of sodium methylparaben and 15 parts of triethanolamine. The triethanolamine and carbomer form a stable emulsion structure to block the skin from forming physical isolation with external bacteria, the sodium methylparaben is used as a bacteriostatic agent and a preservative, and the glycerol is used as a humectant.
According to some embodiments of the invention, the carbomer is selected from one of the following: carbomer 940, carbomer 941, carbomer 934, preferably carbomer 941.
According to some embodiments of the invention, the composition is in the form of one of a paste, a foam, an aerosol, a powder, a solution, an emulsion, and a slurry.
According to some embodiments of the invention, the β -glucan is derived from a yeast cell wall extract and has a molecular weight below 500000D, preferably the β -glucan has a molecular weight below 200000D.
According to some embodiments of the invention, the mannans are derived from yeast cell wall extracts and have a molecular weight below 500000D, preferably the β -glucan has a molecular weight below 200000D.
According to a second aspect of the present invention, the method for preparing the composition comprises the following steps: mixing beta-glucan, mannan, saccharomycetes polypeptides, sodium hyaluronate, carbomer, glycerol, sodium hydroxybenzoate and triethanolamine.
According to an embodiment of the third aspect of the present invention, the use is the use of the above composition for the preparation of a medicament for promoting skin wound healing.
According to some embodiments of the invention, the use is the use of the above composition for the preparation of a medicament for the treatment of scalds.
According to some embodiments of the invention, the use is the use of the above composition for the preparation of a medicament for skin repair.
According to some embodiments of the invention, the use is the use of the above composition for the preparation of a skin care medicament.
According to some embodiments of the invention, the use is in the manufacture of a medicament for the treatment of an oral disease.
According to some embodiments of the invention, the oral disease is dental ulcer, periodontitis, and caries.
A medicament for promoting wound healing of skin, comprising the above composition.
According to some embodiments of the invention, the skin wound healing promoting drug further comprises one or more of a pharmaceutically and/or dermatologically acceptable moisturizer, emollient, surfactant, rheology modifier, skin penetration enhancer, flavoring agent, water soluble film forming polymer, preservative, pH adjustor, or perfume.
The invention has the beneficial effects that: the composition prepared by the invention repairs damaged skin and treats oral diseases through specific synergistic action by beta-glucan, mannans, saccharomycetes polypeptides, sodium hyaluronate, carbomer, glycerol, sodium methylparaben and triethanolamine. The yeast beta-glucan is used for inducing the expression of TNF-alpha in wound macrophages, and the mannan has the functions of resisting viruses, promoting wound healing and resisting oxidization, so that the beta-glucan and the mannan have obvious synergistic effect, can play a remarkable role in skin care and repair, can also effectively inhibit the generation of dental plaque, inhibit the growth of streptococcus mutans, candida stomatitis and porphyromonas, and has remarkable curative effects on dental caries, periodontitis, canker sore and other oral diseases. The beta-glucan and the manna adopted by the scheme of the invention belong to edible grade, are derived from yeast, are natural and safe, and the composition prepared by the scheme of the invention has obvious treatment effects on treating chronic ulcer wounds, superficial wounds, such as sensitive muscles, sunburn skin, acne, diabetic foot, vascular nerve ulcers and the like, treating dental ulcers, periodontitis and gingivitis and preventing dental caries.
Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention.
Drawings
The invention is further described with reference to the accompanying drawings and examples, in which:
FIG. 1 is a graph showing the effect of the composition prepared in example 1 of the test example of the present invention on the cell scratch test;
FIG. 2 is a graph showing the effect of the composition prepared in comparative example 1 in the test example of the present invention on the cell scratch test;
FIG. 3 is a graph showing the effect of the composition prepared in comparative example 2 in the test example of the present invention on the cell scratch test;
FIG. 4 is a graph showing the effect of the composition prepared in comparative example 3 in the test example of the present invention on the cell scratch test;
FIG. 5 is a graph showing the results of treatment of superficial scratches with the composition prepared in example 1 of the test examples of the present invention;
FIG. 6 is a graph showing the treatment results of the composition prepared in example 1 of the test example of the present invention on scalds;
FIG. 7 is a graph showing the effect of the composition prepared in example 1 of the test example of the present invention on staining plaque on teeth before and after brushing.
Detailed Description
The conception and the technical effects produced by the present invention will be clearly and completely described in conjunction with the embodiments below to fully understand the objects, features and effects of the present invention. It is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments, and that other embodiments obtained by those skilled in the art without inventive effort are within the scope of the present invention based on the embodiments of the present invention. The test methods used in the examples are conventional methods unless otherwise specified; the materials, reagents and the like used, unless otherwise specified, are those commercially available.
Example 1
An example of a composition of the invention, this example contains the following components in weight percent: 1% of beta-glucan, 2% of mannan, 1% of saccharomycetes polypeptides, 0.5% of sodium hyaluronate, 941% of carbomer, 3% of glycerol, 0.1% of sodium hydroxybenzoate, 1.5% of triethanolamine and the balance of water.
The preparation method of the composition in this example is as follows:
(1) Adding a proper amount of purified water into a stirring tank, adding 1% carbomer 941, stirring at 80 ℃ to dissolve, preserving heat at 80 ℃ for 30 minutes, starting cooling water, and cooling;
(2) Adding 1% of beta-glucan, 2% of mannan, 1% of saccharomycetes polypeptides, 0.5% of sodium hyaluronate, 3% of glycerol, 0.1% of sodium methylparaben and 1.5% of triethanolamine, and adding the balance of water into a stirring tank to dissolve the components;
(3) Mixing and stirring the mixture obtained in the steps (1) and (2) for 10 minutes.
Example 2
An embodiment of the composition prepared by the invention comprises the following components in percentage by weight: 1% of beta-glucan, 1% of mannan, 1% of saccharomycetes polypeptides, 0.5% of sodium hyaluronate, 941% of carbomer, 3% of glycerol, 0.1% of sodium hydroxybenzoate, 1.5% of triethanolamine and the balance of water.
The method for producing the composition in this example was the same as in example 1.
Example 3
An embodiment of the composition prepared by the invention comprises the following components in percentage by weight: 2% of beta-glucan, 1% of mannan, 1% of saccharomycetes polypeptides, 0.5% of sodium hyaluronate, 941% of carbomer, 3% of glycerol, 0.1% of sodium hydroxybenzoate, 1.5% of triethanolamine and the balance of water.
The method for producing the composition in this example was the same as in example 1.
Example 4
An example of a composition of the invention, this example contains the following components in weight percent: 1% of beta-glucan, 1% of mannan, 1% of saccharomycetes polypeptides, 0.2% of sodium hyaluronate, 941% of carbomer, 2% of glycerol, 0.1% of sodium hydroxybenzoate, 1.5% of triethanolamine and the balance of water.
The method for producing the composition in this example was the same as in example 1.
Example 5
An example of a composition of the invention, this example contains the following components in weight percent: 1% of beta-glucan, 1% of mannan, 0.5% of saccharomycetes polypeptides, 2% of sodium hyaluronate, 941% of carbomer, 1% of glycerol, 0.1% of sodium hydroxybenzoate, 1.5% of triethanolamine and the balance of water.
The method for producing the composition in this example was the same as in example 1.
Comparative example 1
A comparative example of the composition of the present invention, which differs from example 1 only in the removal of beta-glucan from the preparation of the starting material. The sources of the remaining components and the method of making the composition were the same as in example 1.
Comparative example 2
A comparative example of the composition of the present invention, which differs from example 1 only in the removal of mannans from the starting material. The sources of the remaining components and the method of making the composition were the same as in example 1.
Comparative example 3
A comparative example of the composition of the present invention, which differs from example 1 only in the removal of beta-glucan and mannan from the preparation of the starting material. The sources of the remaining components and the method of making the composition were the same as in example 1.
Test case
1. Test for skin repair promoting Activity
(1) Promoting proliferation of Human Skin Fibroblasts (HSF) (MTT assay)
Cells in the logarithmic growth phase were digested, and a cell suspension of 1X 10 5/mL was prepared in DMEM medium containing 10% fetal bovine serum and 1% diabody, inoculated into 96-well plates, and cultured in a 5% CO 2 incubator at 37℃for 24 hours at 150. Mu.L per well, and then the medium was replaced with a 100. Mu.g/mL experimental group, a negative control group (containing an equivalent amount of cell suspension) and a blank control group (containing an equivalent amount of 1% diabody in DMEM medium). The test groups were added with DMEM medium of 1% diabody per well for further culture in example 1, example 2, example 3, comparative example 1, comparative example 2 and comparative example 3, respectively. At least 3 compound wells are arranged in each group, after shaking is carried out uniformly, culture is continued for 24 hours and 48 hours, the culture medium is sucked and removed, PBS is used for washing, 20 mu LMTT solution (5 mg/mL)/well is added, culture is carried out for 4 hours at 37 ℃ by 5% CO 2, supernatant is sucked and removed, 150 mu L of DMSO is added into each well, and shaking table is carried out for 10 minutes, so that the crystal is fully dissolved. The absorbance of each well was measured at 490nm using an enzyme-labeled instrument. Experiments were performed simultaneously in a blank group without sample solution, and proliferation survival was calculated according to the calculation formula shown below, and the experiments were repeated 3 times.
Proliferation survival (%) = (experimental group absorbance value-blank group absorbance value)/(negative control group absorbance value-blank group absorbance value) ×100%.
TABLE 1
Note that: *P＜0.05,**P＜0.01,▲ P > 0.05 compared to the negative control group
The results of the experimental groups on the proliferation survival rate of the HSF at different action times are shown in table 1, and compared with the negative control group, the experimental groups with 24 and 48 hours have proliferation promoting effects (p is less than 0.05) on the HSF, and the effect after 48 hours of administration is better. 24h comparative example 3 has no proliferation promoting effect (p > 0.05), 24h, 48h example 1 has significantly greater proliferation promoting effect on HSF than comparative examples 1,2 and 3, the proliferation promoting effect of example 1 is best, example 3 times, three examples have more significant advantage compared with comparative examples 1 (yeast-deficient beta-glucan), 2 (yeast-deficient mannan) and 3 (yeast-deficient beta-glucan and yeast mannan). Meanwhile, the yeast beta-glucan and yeast mannans have good proliferation promoting effect on human skin fibroblasts when the weight ratio of the yeast beta-glucan to the yeast mannans is 1:2.
(2) Promoting human skin fibroblast migration (cell scratch test)
Cells in the logarithmic growth phase were digested, and a cell suspension having a concentration of 1X 10 5/mL was prepared in a DMEM medium containing 15% fetal bovine serum and 1% diabody, inoculated in 6-well plates, and cultured in 2mL of a 5% CO 2 incubator at 37℃for 24 hours per well, and then gently streaked straight at the center of each well with a 1mL pipette tip, washed with PBS, and then 2mL of a DMEM medium containing 100. Mu.g/mL of the composition (prepared in example 1, control 2 and control 3), 15% fetal bovine serum and 1% diabody was added, and 2mL of a DMEM medium containing 15% fetal bovine serum and 1% diabody was added to the blank, and 3 wells were each multiplexed, and further cultured for 24 hours, and then observed under an inverted microscope and photographed.
The results of the cell scratch test are shown in fig. 1 to 4, and it can be seen from the figures that the cell migration rate is the fastest with the composition prepared in example 1, indicating the most remarkable healing effect on the wound skin.
2. Free radical scavenging Effect test
1. Experimental materials: the compositions prepared in example 1 and comparative examples 1 to 3 were dissolved in water to prepare an aqueous solution having a content of 5% as a sample to be measured.
2. The experimental process comprises the following steps:
(1) Hydroxyl radical scavenging experiments: taking 0.5ml of 0.75mmol/L phenanthroline anhydrous ethanol solution, respectively adding 2ml of 0.2 mol/L phosphate buffer solution (pH=7.4) and 1ml of sample to be detected into a stoppered test tube, fully mixing, adding 0.5ml of 0.75mmol/L FeSO 4·7H2 O solution, mixing again, adding 0.5ml of 0.01% (v/v) H 2O2, reacting for 60min in a constant-temperature water bath at 37 ℃, respectively measuring the absorbance value of each group of mixture solutions at 536nm, marking Ax as a blank group, measuring the absorbance value as Ab with distilled water as a blank group, marking H 2O2 as a damage group, measuring the absorbance value as An, and marking An as An according to the formula: hydroxyl radical clearance = (Ax-An)/(Ab-An) ×100%, and the hydroxyl radical clearance was calculated.
(2) DPPH radical scavenging experiment: taking 3ml of DPPH absolute ethanol solution with the concentration of 0.2mmol/L in a cuvette, adding 1ml of sample to be detected, uniformly mixing, carrying out light-proof reaction at room temperature for 30min, measuring an absorbance value at a wavelength of 517nm, and marking as Ax; taking 3ml of absolute ethyl alcohol and 1ml of a sample to be detected as blank control, measuring an absorbance value, and marking the absorbance value as Ab; the absorbance value was measured using 3ml of DPPH absolute ethanol solution and 1ml of absolute ethanol solution as a control group, and was recorded as An, according to the formula: DPPH radical scavenging rate= [1- (Ax-Ab)/An ] ×100%, DPPH radical scavenging rate was calculated.
TABLE 2 determination of radical scavenging effect of compositions
Note that: p is less than 0.05.
3. Experimental results: the DPPH free radical scavenging results are shown in Table 2, and from the table, the scavenging rate of the composition prepared in the embodiment 1 of the application on the hydroxyl free radical and the DPPH free radical is more than 80%, so that the aging of skin cells can be obviously delayed; whereas comparative examples 1 to 3 show a significant decrease in the scavenging rate of hydroxyl radicals and DPPH radicals, respectively, of the composition components, the technical effect of the present solution is achieved by the synergistic effect of beta-glucan and mannan.
3. In vitro transdermal absorption test
A vertical modified Franz diffusion cell (20 mL) was used for the abdominal ex vivo skin of the suckling pigs. The isolated skin is fixed between the sample cell and the receiving cell, the stratum corneum faces the sample cell, the gel of the test example is uniformly smeared, and the back of the skin is tightly contacted with the receiving liquid (0.9% sodium chloride injection) (no bubbles are needed). The effective diffusion area is about 3cm 2, the receiving system is placed in a constant temperature system at 32+/-0.5 ℃ and is subjected to electromagnetic stirring, and the rotating speed is 400 revolutions per minute. Taking 1mL of the receiving solution at 1h, stopping the test at the same time, immediately taking out the pigskin, cleaning the residual gel on the epidermis, and then fixing the volume of the receiving solution to 10mL. Centrifuging at high speed (10000 rpm) for 5min, collecting supernatant, and filtering to obtain intradermal residue detection solution.
The content of beta-glucan and mannan in the receiving liquid is calculated according to the peak area by an external standard method by adopting an HPLC (high Performance liquid chromatography) differential detection method, and the skin penetration rate is calculated. Transdermal rate = content in the receiving solution/sample content x 100%.
TABLE 3 Table 3
The experimental results are shown in Table 3, from which it can be seen that the formulation of the composition according to the present invention has a remarkable synergistic effect.
4. Bacteriostasis test
The antibacterial activity against oral pathogenic bacteria of example 1 and comparative examples 1 to 3 were tested, taking Porphyromonas pulposus and Streptococcus mutans as examples.
Suspending porphyromonas pulposus in brain heart infusion broth, and culturing at 37 ℃ for 48 hours; streptococcus mutans was suspended in trypticase soy broth and cultured at 37℃for 48 hours; centrifuging at 3000r/min for 10min, removing supernatant, and collecting bacterial liquid. The experiment was divided into 10 groups of physiological saline of example 1, comparative examples 1 to 3 and comparative examples 1 to 3, and samples of example 1 and comparative examples 1 to 3 were prepared as aqueous solutions of equal cell concentrations. Circular filter paper sheets of 6mm diameter sterilized at 121℃for 15min were immersed in 1ml of each of the aqueous solutions and physiological saline solutions of each example and comparative example, respectively, and 5 filter paper sheets of each solution were taken out after 5min and drained. Dipping prepared dental pulp porphyromonas and streptococcus mutans bacterial liquid respectively by using a sterile cotton swab, lightly and parallelly scribing lines in a cross manner in 4 directions on a blood agar plate, and uniformly coating the blood agar plate. Filter paper sheets immersed in different sample solutions were placed on the surface of the inoculated bacterial agar plates, respectively. Each sample was run in duplicate 6 times for each bacterium. The plates were placed in a 37℃incubator for 48h and the diameter of the inhibition ring on each plate was measured with vernier calipers.
TABLE 4 Table 4
Note that: * P is less than 0.05.
As shown in Table 4, it is evident from the table that the inhibitory effects of example 1 on Porphyromonas pulposus and Streptococcus mutans are most remarkable, whereas Porphyromonas and Prevotella are considered as periodontal pathogens, oral microorganisms show that plaque formation is the cause of caries occurrence in teeth, and that acidophilic microorganisms such as Streptococcus mutans are dominant under conditions in which plaque is severely acidified for a long period of time, and that caries formation is remarkably prevented if plaque formation is fundamentally prevented and Streptococcus mutans growth is inhibited. Experimental results show that the composition prepared in the embodiment 1 has good application prospects in preparation of medicines for treating oral diseases.
5. Clinical trial
(1) Experiment for promoting skin wound healing
60 Patients with superficial scratch are selected and randomly divided into an observation group and a control group, 30 patients in each group, and the ages of the patients are between 20 and 55 years. The control group was applied with the commercial skin repair drug and the observation group was applied with example 1, 2 times daily on and around the damaged skin for a total of 10 days.
And (3) observing the indexes: and comparing the treatment effect and the skin function detection result of the two groups of patients.
The effect is shown: the damaged skin is healed completely after the treatment of the patient, and no scar remains.
The method is effective: the damaged skin heals completely after the treatment of the patient, and the scar is obviously improved.
Invalidation: the damaged skin was not improved after treatment of the patient.
Results: the control group had significantly lower treatment effect than the observed group, no statistical difference in data between groups (p < 0.05), and the patient treatment effect is shown in Table 5:
TABLE 5
Note that: p < 0.05.
As can be seen from Table 5, the observed group had better wound skin repair effect than the control group, and the data from group to group were statistically significant (p < 0.05).
1 Example of a superficial scratch patient aged 5 is selected, the composition prepared in the embodiment 1 of the scheme of the application is smeared on the patient for informed consent, the experimental result is shown in fig. 5, and the wound is recovered to be normal after the scratch patient is used for 3 days.
(2) Effect of applying scald
1 Example of a patient with scalds is selected, the composition prepared in the embodiment 1 of the scheme of the application is smeared 3 times daily for uniformly covering the surface skin for informed consent patients, the experimental result is shown in fig. 6, and the wound healing and the surface skin are basically recovered to be normal after the patient with scalds is used for 10 days as can be seen from the figure.
(3) Experiments to inhibit plaque formation
20 Subjects 20 to 55 years old were selected, and plaque staining effect of plaque on teeth before and after brushing with the composition prepared in example 1 was compared by plaque disclosing solution (trade name Yan Di of Wuhan ya Biotechnology Co., ltd.). The experimental results are shown in fig. 7, and it can be seen from the graph that after brushing teeth for 2-3 minutes each day using the composition prepared in example 1, the red dental plaque attached to the teeth is significantly reduced after 1 month, which indicates that the composition prepared in the scheme of the invention can inhibit the formation of dental plaque on the tooth surface, and can effectively prevent caries, halitosis and stomatitis.
The yeast beta-glucan and yeast mannan used in the examples and comparative examples of the present invention are commercially available conventional products.
The embodiments of the present invention have been described in detail with reference to the accompanying drawings, but the present invention is not limited to the above embodiments, and various changes can be made within the knowledge of one of ordinary skill in the art without departing from the spirit of the present invention. Furthermore, embodiments of the invention and features of the embodiments may be combined with each other without conflict.
Claims (5)
1. The composition is characterized by comprising the following preparation raw materials in percentage by weight: 1% of beta-glucan, 2% of mannan, 1% of saccharomycetes polypeptides, 0.5% of sodium hyaluronate, 941% of carbomer, 3% of glycerol, 0.1% of sodium hydroxybenzoate, 1.5% of triethanolamine and 89.9% of water.
2. A method of preparing the composition of claim 1, comprising the steps of:
s1: adding part of water into a stirring tank, adding 1% carbomer 941, stirring at 80deg.C to dissolve, maintaining at 80deg.C for 30 min, starting cooling water, and cooling to obtain mixture 1;
S2: adding 1% of beta-glucan, 2% of mannan, 1% of saccharomycetes polypeptides, 0.5% of sodium hyaluronate, 3% of glycerol, 0.1% of sodium methylparaben, 1.5% of triethanolamine and the balance of water into a stirring tank to dissolve all the components, so as to obtain a mixture 2;
S3: and (3) mixing and stirring the mixture 1 obtained in the step (S1) and the mixture 2 obtained in the step (S2) for 10 minutes to obtain the composition.
3. Use of a composition according to claim 1 for the preparation of a medicament for promoting skin wound healing.
4. Use of a composition according to claim 1 for the preparation of a medicament for the treatment of scalds.
5. Use of a composition according to claim 1 for the preparation of a medicament for the treatment of oral diseases, such as canker sores, periodontitis and caries.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111163063.5A CN113813367B (en) | 2021-09-30 | 2021-09-30 | Composition for treating sensitive skin and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111163063.5A CN113813367B (en) | 2021-09-30 | 2021-09-30 | Composition for treating sensitive skin and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113813367A CN113813367A (en) | 2021-12-21 |
| CN113813367B true CN113813367B (en) | 2024-05-28 |
Family
ID=78916264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111163063.5A Active CN113813367B (en) | 2021-09-30 | 2021-09-30 | Composition for treating sensitive skin and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113813367B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115518004B (en) * | 2022-01-13 | 2024-01-16 | 海尼达(江苏)医疗科技有限公司 | Composition for assisting in improving oral health and application thereof |
| CN115590787B (en) * | 2022-10-13 | 2023-12-26 | 湖南天根乐微君科技有限公司 | Composition for acne removal and skin repair as well as preparation method and application thereof |
| CN115501246B (en) * | 2022-10-31 | 2023-08-08 | 湖南天根乐微君科技有限公司 | Composition capable of effectively repairing, desalting and removing scars and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2304815A1 (en) * | 1997-10-24 | 1999-05-06 | Brennen Medical, Inc. | .beta.-d glucan topical composition |
| CN1425691A (en) * | 2001-12-14 | 2003-06-25 | 中国科学院微生物研究所 | Acetyl mannan and its preparing method and use |
| CN103007337A (en) * | 2012-12-31 | 2013-04-03 | 凌峰 | Polymer dressing and dressing patch |
| CN112023116A (en) * | 2020-08-31 | 2020-12-04 | 海南鸿翼医疗器械有限公司 | Skin barrier paste dressing and preparation method thereof |
| CN112402443A (en) * | 2019-08-22 | 2021-02-26 | 浙江立恩生物科技有限公司 | Biological polysaccharide for preventing and treating oral diseases and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070166242A1 (en) * | 2005-12-19 | 2007-07-19 | Kross Robert D | Oral care product and method for the reduction of dental caries through inclusion of mannan and galactomannan polysaccharides in dentifrice formulations |
-
2021
- 2021-09-30 CN CN202111163063.5A patent/CN113813367B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2304815A1 (en) * | 1997-10-24 | 1999-05-06 | Brennen Medical, Inc. | .beta.-d glucan topical composition |
| CN1425691A (en) * | 2001-12-14 | 2003-06-25 | 中国科学院微生物研究所 | Acetyl mannan and its preparing method and use |
| CN103007337A (en) * | 2012-12-31 | 2013-04-03 | 凌峰 | Polymer dressing and dressing patch |
| CN112402443A (en) * | 2019-08-22 | 2021-02-26 | 浙江立恩生物科技有限公司 | Biological polysaccharide for preventing and treating oral diseases and application thereof |
| CN112023116A (en) * | 2020-08-31 | 2020-12-04 | 海南鸿翼医疗器械有限公司 | Skin barrier paste dressing and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| β-葡聚糖的性质及其在化妆品中的应用;郦伟章;香料香精化妆品;19990815(03);第35-38页 * |
| 几种低聚糖在化妆品中的应用研究;李欣航等;香料香精化妆品(第3期);第70-74，84页 * |
| 葡聚糖作为新型医用敷料的应用研究与前景;王小林等;中国组织工程研究;第21卷(第26期);第4252-4257页 * |
| 酵母多肽的分离纯化及其化妆品功效研究;付豪;刘平平;朱剑锋;李燕龙;李萌;王昌涛;;湖北农业科学;20200410(07);第184-187+217页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113813367A (en) | 2021-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113813367B (en) | Composition for treating sensitive skin and preparation method and application thereof | |
| JP4194116B2 (en) | Process for the preparation of silicon compounds having biological activity in concentrated form | |
| EP2397125A1 (en) | Antioxidant composition | |
| JP6058588B2 (en) | Process for the purification of heparan sulfate and its use in cosmetic and dermatological preparations | |
| CN113332162B (en) | protamine-PDRN compound, composition and application in preparation of skin care product | |
| CN111840176A (en) | A skin caring composition with effects of resisting glycosylation, whitening skin, removing speckle and removing wrinkle, and its application | |
| JPH09295928A (en) | Cosmetic material for prevention of aging | |
| CN111494466A (en) | A topical composition containing Cannabis sativa extract and its application | |
| RU2470640C1 (en) | Agent for treating inflammatory oral diseases and method of treating inflammatory oral diseases | |
| CN111743826A (en) | Freckle-removing, wrinkle-resisting and moisturizing emulsion | |
| CN113648251A (en) | Skin repairing composition and preparation method thereof | |
| JP3213189B2 (en) | Hyaluronic acid production promoter | |
| JP3170040B2 (en) | Whitening cosmetics | |
| JP3235922B2 (en) | Cosmetics | |
| CN113171316B (en) | Cosmetic for repairing and relieving skin irritation and preparation method thereof | |
| CN113546031B (en) | Composition for promoting stratum corneum regeneration and preparation method and application thereof | |
| CN115501246A (en) | Composition and preparation method and application thereof | |
| KR20080079489A (en) | Cosmetic compositions containing hollyhock extracts | |
| CN114306125A (en) | Composition containing schizophyllan with different molecular weights as well as preparation method and application thereof | |
| CN114042010A (en) | Enzyme preparation cutin removing cream and preparation method thereof | |
| KR20140145274A (en) | Composition for skin moisturizing containing oxygen dissolving water with a polymer composition | |
| CN109044933B (en) | Application of dragon's blood extract in preparing toothpaste for inhibiting dental plaque | |
| JP2681467B2 (en) | Topical composition containing human leukocyte interferon | |
| CN107982300B (en) | Spray and preparation method and application thereof | |
| JPH06189780A (en) | Hyaluronic acid production promoting agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |